History

Our Accomplishments:

Sorrento has had a long journey from a humble beginning to a diversified biopharma discovering and developing life changing medicine.

2009

Founded

2013

Acquired Resiniferatoxin (RTX) assets via the acquisition of Sherrington Pharmaceuticals Inc.
Acquired Antibody Drug Conjugation (ADC) technologies via acquisition of Concortis Biosystems Corp.

2014

Out-licensed PD-L1 for Greater China market to Lee’s Pharm

2015

In-licensed Erbitux®, Remicade®, Xolair®, Simulect® biosimilar candidates from Mabtech Limited

2016

Formed ImmuneOncia JV with Yuhan Pharmaceuticals
Acquired ZTlido® via majority stake in Scilex Pharmaceuticals
Acquired Bioserv Corporation for cGMP manufacturing operations
Formed Levena Suzhou Biopharma Co. LTD for Antibody Drug Conjugation (ADC) services

2017

Acquired Oncolytic Virus platform via the acquisition of Virttu Biologics Limited
Formed Celularity with Celgene and United Therapeutics

2018

Acquired Sofusa® Lymphatic Delivery System from Kimberly-Clark

2019

Acquired Semnur Pharmaceuticals
Formed Scilex Holding to consolidate the merger of Scilex Pharma and Semnur Pharma
Established CBD JV with LifeTech Scientific